

Message

From: Pierce, Amanda [pierce.amanda@epa.gov]
Sent: 2/11/2020 5:52:08 PM
To: Mendelsohn, Mike [Mendelsohn.Mike@epa.gov]
CC: Bohnenblust, Eric [Bohnenblust.Eric@epa.gov]
Subject: FW: Follow-Up re: EPA-CDC discussion on oxitec
Attachments: CDC summary comments for EPA - oxitec proposal.docx; 93167-EUP-R disease transmission memo 02.11.20.docx

Importance: High

Hi Mike,

I have updated the memo based on CDC comments. I have not updated the memo to address their 2nd point, although they did not specifically ask for anything to be added. I'm also still not sure if I have their titles correct on the signature lines. We can discuss more at the Oxitec regroup meeting this afternoon.

Amanda

From: Beard, Charles (Ben) (CDC/DDID/NCEZID/DVBD) <cbb0@cdc.gov>
Sent: Friday, February 7, 2020 5:58 PM
To: Mendelsohn, Mike <Mendelsohn.Mike@epa.gov>
Cc: McNally, Robert <Mcnally.Robert@epa.gov>; Overstreet, Anne <overstreet.anne@epa.gov>; Bohnenblust, Eric <Bohnenblust.Eric@epa.gov>; Jennings, Susan <Jennings.Susan@epa.gov>; Pierce, Amanda <pierce.amanda@epa.gov>; Striegel, Wiebke <Striegel.Wiebke@epa.gov>; Wozniak, Chris <wozniak.chris@epa.gov>; McAllister, Janet (CDC/DDID/NCEZID/DVBD) <jvm6@cdc.gov>; Powers, Ann (CDC/DDID/NCEZID/DVBD) <akp7@cdc.gov>; Brault, Aaron C. (CDC/DDID/NCEZID/DVBD) <zlu5@cdc.gov>; Beard, Charles (Ben) (CDC/DDID/NCEZID/DVBD) <cbb0@cdc.gov>
Subject: RE: Follow-Up re: EPA-CDC discussion on oxitec
Importance: High

Dear Mike,

We have completed peer review of the materials you sent us regarding the EUP application for Oxitec OX5034. Please see the attached summary, which was compiled by Dr. Ann Powers and represents comments that were provided by Ann Powers, Aaron Brault, Janet McAllister, and me. Thanks for the opportunity to provide input.

Sincerely,
Ben Beard

C. Ben Beard, MS, Ph.D.
Deputy Director
Division of Vector-Borne Diseases
CDC
Mail Stop P-02
3156 Rampart Road
Fort Collins, CO 80521 USA
Phone: (970) 221-6418
Cell phone: (970) 567-0980
Fax: (970) 266-3599
E-mail: cbeard@cdc.gov

From: Mendelsohn, Mike <Mendelsohn.Mike@epa.gov>

Sent: Thursday, January 23, 2020 12:27 PM

To: Beard, Charles (Ben) (CDC/DDID/NCEZID/DVBD) <cbb0@cdc.gov>; Brault, Aaron C. (CDC/DDID/NCEZID/DVBD) <zlu5@cdc.gov>; Connelly, C. Roxanne (CDC/DDID/NCEZID/DVBD) <csz5@cdc.gov>; Powers, Ann (CDC/DDID/NCEZID/DVBD) <akp7@cdc.gov>; McAllister, Janet (CDC/DDID/NCEZID/DVBD) <jvm6@cdc.gov>; Barrera, Roberto (CDC/DDID/NCEZID/DVBD) <amz9@cdc.gov>

Cc: McNally, Robert <McNally.Robert@epa.gov>; Overstreet, Anne <overstreet.anne@epa.gov>; Bohnenblust, Eric <Bohnenblust.Eric@epa.gov>; Jennings, Susan <Jennings.Susan@epa.gov>; Pierce, Amanda <pierce.amanda@epa.gov>; Striegel, Wiebke <Striegel.Wiebke@epa.gov>; Wozniak, Chris <wozniak.chris@epa.gov>

Subject: FW: Follow-Up re: EPA-CDC discussion on oxitec

Ben,

Per our discussion, I am sending you our draft assessment regarding vectorial capacity for the Oxitec mosquito experimental use permit application. In addition to the material in this email, please refer to the CD given to you last week by Eric Bohnenblust that has Oxitec's data/rational submitted to EPA and referenced in the draft assessment.

We hope to receive CDC's peer review of this assessment by 2/6/20. The plan, once we incorporate CDC edits, would be for all reviewers at EPA and CDC to sign via PDF. Amanda Pierce is our lead risk assessor for this issue and technical questions and discussion about the review should be directed to her. Thanks so much for CDC's support on this and the technical expertise your bring to the table. Much appreciated!

Best Regards,

Mike Mendelsohn, Chief
Emerging Technologies Branch
Biopesticides and Pollution Prevention Division (7511P)
Office of Pesticide Programs
U.S. Environmental Protection Agency
1200 Pennsylvania Avenue NW
Washington DC 20460
(703) 308-8715
(703) 463-7302 Mobile